Current and future perspectives of PD‐1/PDL‐1 blockade in cancer immunotherapy
Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has
yielded great success in recent years. Among immunotherapeutic agents, immune …
yielded great success in recent years. Among immunotherapeutic agents, immune …
Multiple myeloma: an overview of management
SA Bird, K Boyd - Palliative care and social practice, 2019 - journals.sagepub.com
Multiple myeloma represents 2% of all new cancer diagnoses in the United Kingdom and
accounts for 2% of all cancer deaths. In the past few decades, there have been huge …
accounts for 2% of all cancer deaths. In the past few decades, there have been huge …
CAR-T cell therapies: an overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large B-cell lymphomas
Chimeric Antigen Receptor (CAR)-T cell therapy is an exciting development in the field of
cancer immunology, wherein immune T-cells from patients are collected, engineered to …
cancer immunology, wherein immune T-cells from patients are collected, engineered to …
Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid tumors
A Cheever, M Townsend, K O'Neill - Cells, 2022 - mdpi.com
Chimeric antigen receptor (CAR) T cells are an exciting advancement in cancer
immunotherapy, with striking success in hematological cancers. However, in solid tumors …
immunotherapy, with striking success in hematological cancers. However, in solid tumors …
[HTML][HTML] HSF1 Inhibits Antitumor Immune Activity in Breast Cancer by Suppressing CCL5 to Block CD8+ T-cell Recruitment
C Jacobs, S Shah, WC Lu, H Ray, J Wang… - Cancer Research, 2024 - AACR
Abstract Heat shock factor 1 (HSF1) is a stress-responsive transcription factor that promotes
cancer cell malignancy. To provide a better understanding of the biological processes …
cancer cell malignancy. To provide a better understanding of the biological processes …
[HTML][HTML] Principles for the design of multicellular engineered living systems
Remarkable progress in bioengineering over the past two decades has enabled the
formulation of fundamental design principles for a variety of medical and non-medical …
formulation of fundamental design principles for a variety of medical and non-medical …
Alternative CAR therapies: recent approaches in engineering chimeric antigen receptor immune cells to combat cancer
For nearly three decades, chimeric antigen receptors (CARs) have captivated the interest of
researchers seeking to find novel immunotherapies to treat cancer. CARs were first …
researchers seeking to find novel immunotherapies to treat cancer. CARs were first …
Update for advance CAR-T therapy in solid tumors, clinical application in peritoneal carcinomatosis from colorectal cancer and future prospects
S Qian, P Villarejo-Campos, I Guijo… - Frontiers in …, 2022 - frontiersin.org
Latest advances in the field of cancer immunotherapy have developed the (Chimeric
Antigen Receptor) CAR-T cell therapy. This therapy was first used in hematological …
Antigen Receptor) CAR-T cell therapy. This therapy was first used in hematological …
CAR-NK as a rapidly developed and efficient immunotherapeutic strategy against cancer
M Włodarczyk, B Pyrzynska - Cancers, 2022 - mdpi.com
Simple Summary New approaches in adoptive immunotherapy using chimeric antigen
receptor (CAR)-modified cells have been developing very quickly in recent years, entering …
receptor (CAR)-modified cells have been developing very quickly in recent years, entering …
Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition
Chimeric antigen receptor (CAR) T cell show promise in cancer treatments, but their
mechanism of action is not well understood. Decoding the mechanisms used by individual T …
mechanism of action is not well understood. Decoding the mechanisms used by individual T …